TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Kala Pharmaceuticals
US Patent
Kala Pharmaceuticals
US Patent
Affinity DataKd: 490nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Target InfoPDBMMDBNCI pathwayReactome pathwayKEGG
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
Ligand Info
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Kala Pharmaceuticals
US Patent
Kala Pharmaceuticals
US Patent
Affinity DataKd: 1.00E+4nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Target InfoPDBMMDBNCI pathwayReactome pathwayKEGG
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
Ligand Info
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Kala Pharmaceuticals
US Patent
Kala Pharmaceuticals
US Patent
Affinity DataKd: 3.70E+4nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Target InfoPDBMMDBNCI pathwayReactome pathwayKEGG
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
Ligand Info
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Kala Pharmaceuticals
US Patent
Kala Pharmaceuticals
US Patent
Affinity DataKd: 2.00E+4nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Target InfoPDBMMDBNCI pathwayReactome pathwayKEGG
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
Ligand Info
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Kala Pharmaceuticals
US Patent
Kala Pharmaceuticals
US Patent
Affinity DataKd: 520nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Target InfoPDBMMDBNCI pathwayReactome pathwayKEGG
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
Ligand Info
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Kala Pharmaceuticals
US Patent
Kala Pharmaceuticals
US Patent
Affinity DataKd: 1.00E+3nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Target InfoPDBMMDBNCI pathwayReactome pathwayKEGG
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
Ligand Info
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Kala Pharmaceuticals
US Patent
Kala Pharmaceuticals
US Patent
Affinity DataKd: 5.80E+4nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Target InfoPDBMMDBNCI pathwayReactome pathwayKEGG
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
Ligand Info
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Kala Pharmaceuticals
US Patent
Kala Pharmaceuticals
US Patent
Affinity DataKd: 4.80E+3nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Target InfoPDBMMDBNCI pathwayReactome pathwayKEGG
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
Ligand Info
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Kala Pharmaceuticals
US Patent
Kala Pharmaceuticals
US Patent
Affinity DataKd: 690nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Target InfoPDBMMDBNCI pathwayReactome pathwayKEGG
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
Ligand Info
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Kala Pharmaceuticals
US Patent
Kala Pharmaceuticals
US Patent
Affinity DataKd: 1.30E+3nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Target InfoPDBMMDBNCI pathwayReactome pathwayKEGG
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
Ligand Info
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Kala Pharmaceuticals
US Patent
Kala Pharmaceuticals
US Patent
Affinity DataKd: 1.00E+4nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Target InfoPDBMMDBNCI pathwayReactome pathwayKEGG
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
Ligand Info
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Kala Pharmaceuticals
US Patent
Kala Pharmaceuticals
US Patent
Affinity DataKd: 3.10E+4nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Target InfoPDBMMDBNCI pathwayReactome pathwayKEGG
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
Ligand Info
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Kala Pharmaceuticals
US Patent
Kala Pharmaceuticals
US Patent
Affinity DataKd: 8.70E+3nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Target InfoPDBMMDBNCI pathwayReactome pathwayKEGG
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
Ligand Info
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Kala Pharmaceuticals
US Patent
Kala Pharmaceuticals
US Patent
Affinity DataKd: 1.40E+4nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Target InfoPDBMMDBNCI pathwayReactome pathwayKEGG
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
Ligand Info
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Kala Pharmaceuticals
US Patent
Kala Pharmaceuticals
US Patent
Affinity DataKd: 980nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Target InfoPDBMMDBNCI pathwayReactome pathwayKEGG
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
Ligand Info
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Kala Pharmaceuticals
US Patent
Kala Pharmaceuticals
US Patent
Affinity DataKd: 2.50E+4nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Target InfoPDBMMDBNCI pathwayReactome pathwayKEGG
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
Ligand Info
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Kala Pharmaceuticals
US Patent
Kala Pharmaceuticals
US Patent
Affinity DataKd: 1.20E+5nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Target InfoPDBMMDBNCI pathwayReactome pathwayKEGG
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
Ligand Info
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Kala Pharmaceuticals
US Patent
Kala Pharmaceuticals
US Patent
Affinity DataKd: 3.30E+3nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Target InfoPDBMMDBNCI pathwayReactome pathwayKEGG
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
Ligand Info
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Kala Pharmaceuticals
US Patent
Kala Pharmaceuticals
US Patent
Affinity DataKd: 2.70E+4nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Target InfoPDBMMDBNCI pathwayReactome pathwayKEGG
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
Ligand Info
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Kala Pharmaceuticals
US Patent
Kala Pharmaceuticals
US Patent
Affinity DataKd: 1.70E+3nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Target InfoPDBMMDBNCI pathwayReactome pathwayKEGG
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
Ligand Info
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Kala Pharmaceuticals
US Patent
Kala Pharmaceuticals
US Patent
Affinity DataKd: 2.40E+3nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Target InfoPDBMMDBNCI pathwayReactome pathwayKEGG
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
Ligand Info
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Kala Pharmaceuticals
US Patent
Kala Pharmaceuticals
US Patent
Affinity DataKd: 1.30E+3nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Target InfoPDBMMDBNCI pathwayReactome pathwayKEGG
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
Ligand Info
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Kala Pharmaceuticals
US Patent
Kala Pharmaceuticals
US Patent
Affinity DataKd: 3.20E+3nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Target InfoPDBMMDBNCI pathwayReactome pathwayKEGG
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
UniProtKB/SwissProt
B.MOADDrugBankantibodypediaGoogleScholar
Ligand Info